title: High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: The role of pleiotrophin.
abstract: The aim of the present study was to investigate the effect of a high-glucose-based peritoneal dialysis solution (HGPDS) on the expression of pleiotrophin (PTN) and vascular endothelial growth factor (VEGF) in human peritoneal mesothelial cells (HPMCs) and the mechanisms through which fluvastatin (Flu) protects the peritoneal membrane in continuous ambulatory peritoneal dialysis (CAPD). HPMCs were cultured with HGPDS, Flu (10-8‑10-6 mol/l) and PTN (10‑30 nmol/l). The expression of PTN and VEGF was examined at the mRNA and protein level. To define the role of PTN in the regulation of VEGF expression, HPMCs were cultured with HGPDS in the presence or absence of the blocking peptide of PTN. The signaling pathways involved in PTN synthesis induced by HGPDS were also characterized. The phenotypic characteristics of HPMCs were observed under a light microscope. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetry and the mRNA and protein expression of PTN, VEGF and ERK1/2 was assessed by RT‑PCR and the western blot analysis, respectively. Following incubation with HGPDS for 48 h, the morphology of the HPMCs changed from a typical cobblestone‑like appearance to a fibroblast‑like phenotype. The same alteration in the morphology of the HPMCs also occurred following incubation with 20 nmol/l PTN. Flu (10-6 mol/l), GSK650394 [a competitive inhibitor of serum/glucocorticoid-regulated kinase 1 (SGK1), 10-5 mol/l] and PD98059 (a competitive inhibitor of ERK1/2, 10-5 mol/l) improved the negative changes in cell morphology induced by HGPDS. The results of MTT assay revealed that the reduction in HPMC viability occurred in the groups treated with HGPDS and this reduction was partially restored by Flu, GSK650394 and PD98059. A significant improvement in cell viability, which had been decreased by HGPDS, was observed following treatment with Flu (10-6 mol/l), PD98059 (10-5 mol/l) or GSK650394 (10-5 mol/l) (P<0.05). Compared with the control, the mRNA and protein expression of PTN and VEGF significantly increased in the HPMCs treated with HGPDS (P<0.05). GSK650394 and PD98059 significantly decreased the high mRNA and protein expression levels of PTN and VEGF induced by HGPDS (P<0.05) and Flu had the same inhibitory effect as GSK650394 and PD98059 in a dose‑dependent manner (P<0.05). The mRNA and protein expression of VEGF increased following the incubation of HPMCs with 20 nmol/l PTN. By contrast, the mRNA and protein expression levels of VEGF in the HPMCs decreased in the presence of the blocking peptide of PTN. The results from the present study indicated that HGPDS increased the expression of PTN and VEGF in the HPMCs, and this increase was attenuated by Flu, GSK650394 and PD98059. The protein expression of phosphorylated ERK1/2 (p-ERK1/2) was decreased by GSK650394 in the HPMCs treated with HGPDS. Taken together, the protective effects of Flu in HPMCs may be partially achieved through the SGK1‑ERK1/2 signaling pathway.
authors.affiliation: Department of Nephrology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
authors.forename: Jia
authors.initials: J
authors.lastname: Liu
authors.forename: Xia
authors.initials: X
authors.lastname: Wu
authors.forename: Yanchun
authors.initials: Y
authors.lastname: Liu
authors.forename: Yaguang
authors.initials: Y
authors.lastname: Xu
authors.forename: Yuhan
authors.initials: Y
authors.lastname: Huang
authors.forename: Changying
authors.initials: C
authors.lastname: Xing
authors.forename: Xiaoyun
authors.initials: X
authors.lastname: Wang
mesh_terms: D002352:Carrier Proteins / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D016207:Cytokines / Q000378:metabolism* / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D010529:Peritoneal Cavity / Q000166:cytology; D010530:Peritoneal Dialysis / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D002352:Carrier Proteins; D016207:Cytokines; D042461:Vascular Endothelial Growth Factor A; C066845:pleiotrophin; D005947:Glucose